MIAMI, Jan. 10,
2025 /PRNewswire/ -- HOPE Therapeutics™, Inc.,
("HOPE"), a medical and technology driven company, and a
wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and
collectively with HOPE, the "Company") (Nasdaq:NRXP), today
announced it conducted an investor workshop to support planned
expansion of HOPE's network of interventional psychiatry practices
focused on the treatment of suicidal depression and PTSD, at the
Mar-A-Lago Club in Palm Beach,
FL.
The event was attended by Qualified Institutional Buyers as
defined by the Securities and Exchange Commission and included
Jonathan Javitt, MD, MPH, Chairman
and CEO of NRx together with Dallas
Sauer, Founder of Smith and Sauer, the private investment
firm that recently committed to invest in both NRx and HOPE. No
formal meetings were conducted with members of the incoming
administration.
Key areas of investor discussions included:
- HOPE's mission to build an international network of best-in
class, EBITDA positive, interventional psychiatry clinics
- $25 million financing committed
by Smith and Sauer (JGS Holdings LLC) to leverage anticipated bank
financing projected to secure $100
million in HOPE clinic revenue stream on a pro-forma
basis
- Recently announced progress for HOPE's initial clinic
acquisitions
- Potential mechanisms for follow-on non-dilutive financing to
expand HOPE's network by an additional 50 clinics in 2026 and 100
clinics in 2027
- Plans for integration of new technologies and a CRM-based
information technology and telepsychiatry umbrella to span the HOPE
network
Based on the results of today's meeting, NRx has been invited to
return to Mar-A-Lago for an expanded meeting during the last week
of January 2025 that will include
both Qualified Institutional Buyers and Accredited Investors.
Individuals interested in attending are invited to contact
Matthew Duffy, Co-CEO of HOPE
Therapeutics.
"We were gratified by the enthusiastic response and inciteful
questions we received from this group of sophisticated attendees
and look forward to future discussions," said Jonathan Javitt, MD MPH, Founder, Chairman &
CEO of NRx, and Co-CEO HOPE
Therapeutics. "Our mission to treat and prevent suicidality
in our society in general, and our military/veteran communities in
particular, clearly resonated with those who joined us this
evening."
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a
development stage healthcare delivery company that intends to
develop a best-in-class network of interventional psychiatry
clinics to offer ketamine transcranial magnetics stimulation (TMS)
and other lifesaving therapies to patients with suicidal depression
and related disorders, together with a digital therapeutic-enabled
platform designed to augment and preserve the clinical benefit of
NMDA-targeted drug therapy.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical
company developing therapeutics based on its NMDA platform for the
treatment of central nervous system disorders, specifically
suicidal bipolar depression, chronic pain, and PTSD. The Company is
developing NRX-101, an FDA-designated investigational Breakthrough
Therapy for suicidal treatment-resistant bipolar depression and
chronic pain. NRx plans to file an NDA for Accelerated Approval for
NRX-101 in patients with bipolar depression and suicidality or
akathisia. NRX-101 additionally has potential to act as a
non-opioid treatment for chronic pain, as well as a treatment for
complicated UTI.
NRx has recently announced initiation of filing a New Drug
Application for NRX-100 (IV ketamine) for the treatment of suicidal
depression, based on results of well-controlled clinical trials
conducted under the auspices of the US National Institutes of
Health and newly obtained data from French health authorities,
licensed under a data sharing agreement. NRx was awarded Fast Track
Designation for development of ketamine (NRX-100) by the US FDA as
part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and Section 27A of the Securities
Act of 1933, as amended. These statements include, among others,
statements regarding closing the acquisition of Kadima and
obtaining financing necessary to consummate the acquisition.
Forward-looking statements generally include statements that are
predictive in nature and depend upon or refer to future events or
conditions, and include words such as "may," "will," "should,"
"would," "expect," "plan," "believe," "intend," "look forward," and
other similar expressions among others. These statements relate to
future events or to the Company's future financial performance, and
involve known and unknown risks, uncertainties and other factors
that may cause the Company's actual results to be materially
different from any future results, levels of activity, performance
or achievements expressed or implied by these forward-looking
statements. You should not place undue reliance on forward-looking
statements since they involve known and unknown risks,
uncertainties and other factors which are, in some cases, beyond
the Company's control and which could, and likely will, materially
affect actual results, levels of activity, performance or
achievements. Any forward-looking statement reflects the Company's
current views with respect to future events and is subject to these
and other risks, uncertainties and assumptions relating to the
Company's operations, results of operations, growth strategy,
liquidity, Hope Therapeutic's ability to consummate the
acquisitions of providers for its national network, the Company's
ability to raise adequate capital to fund the Hope Therapeutics
acquisitions, and the Company's ability to spin-off Hope
Therapeutics. More detailed information about the Company and the
risk factors that may affect the realization of forward-looking
statements is set forth in the Company's most recent Annual Report
on Form 10-K and other filings with the Securities and Exchange
Commission. Investors and security holders are urged to read these
documents free of charge on the SEC's website
at http://www.sec.gov. Except as may be required by applicable
law, The Company assumes no obligation to publicly update or revise
these forward-looking statements for any reason, or to update the
reasons actual results could differ materially from those
anticipated in these forward-looking statements, whether as a
result of new information, future events or otherwise.
For further information:
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE
Therapeutics, Inc.
mduffy@nrxpharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-conduct-investor-workshop-at-the-mar-a-lago-club-302347792.html
SOURCE NRx Pharmaceuticals, Inc.
